Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors

NCT06837389 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Hematological Malignancies

Interventions

BIOLOGICAL: JY306 universal NK cell injection

Sponsor

The First Affiliated Hospital with Nanjing Medical University